Postherpetic Neuralgia (PHN)

EFFICACY IN PHN
In an 8-week pivotal study, LYRICA (pregabalin) provided powerful relief in PHN1,2
8 week relief in PHN
*LYRICA 300 mg/day and 600 mg/day, divided TID.
Baseline observation carried forward (BOCF) analysis of intent-to-treat population.
Patients with low creatinine clearance (>30 and ≤60 mL/min; n=30) received a maximum dosage of LYRICA 300 mg/day, but were analyzed with the 600 mg/day group having normal creatinine clearance (>60 mL/min; n=59).
Study description
In the same 8-week pivotal study, LYRICA cut PHN pain in half1,2*
8 week relief in PHN half
LYRICA 300 mg/day and 600 mg/day, divided TID.
Baseline observation carried forward (BOCF) analysis of intent-to-treat population.
Patients with low creatinine clearance (>30 and ≤60 mL/min; n=30) received a maximum dosage of LYRICA 300 mg/day, but were analyzed with the 600 mg/day group having normal creatinine clearance (>60 mL/min; n=59).
*Over 1.5x more patients on LYRICA achieved a PHN pain reduction of 50% or more vs those on placebo1,2
Study description
DOSING IN PHN
Consider your next steps for LYRICA titration, based on efficacy and tolerability
dosing in PHN chart
Dosage may be increased to 300 mg/day based on efficacy and tolerability within 1 week
Patients may be titrated to 600 mg/day if they are not experiencing sufficient pain relief after 2 to 4 weeks of treatment with 300 mg/day
When discontinuing LYRICA, taper gradually over a minimum of 1 week
Adjust the LYRICA daily dose based on renal function
SAFETY IN PHN
In controlled trials in adults with PHN,
Adverse reactions were generally mild to moderate1
safety in PHN chart
safety in PHN chart
safety in PHN chart
safety in PHN chart
safety in PHN chart
safety in PHN chart
LYRICA was administered in doses divided BID or TID.
*Includes all doses of LYRICA that were studied in PHN (eg, 75 mg/day).
Reactions in ≥5% of all LYRICA-treated patients and occurring at least twice the rate of placebo.
In LYRICA clinical trials of postherpetic neuralgia, 14% of LYRICA-treated patients and 7% of placebo-treated patients discontinued due to adverse reactions.
Clinical Background
With the Co-Pay Savings Card, eligible patients may pay as little as $4 per Rx for branded LYRICA.
 
See terms and conditions below for full eligibility requirements.
*Includes patients who received any study dose of LYRICA in placebo-controlled studies of fibromyalgia, painful diabetic peripheral neuropathy, postherpetic neuralgia, and neuropathic pain associated with spinal cord injury, as well as open-label extensions of those studies.
References: 1. Data on file. Pfizer Inc., New York, NY. 2. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274-1283.